Home > News > featured news > Thermo Fisher Scientific Highlights Growing Capacity for Biologics, Cell and Gene Therapy Production During BIO 2020

Thermo Fisher Scientific Highlights Growing Capacity for Biologics, Cell and Gene Therapy Production During BIO 2020

PR Newswire | June 08, 2020

For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital. "We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccines, antivirals and other therapies," said Mike Shafer, senior vice president and president, pharma services, Thermo Fisher Scientific. "Through our recent strategic initiatives, we are delivering to our customers a powerful combination of expertise, flexibility and scale that allows us to be the partner they start with and stay with." Earlier this year, the company announced plans to invest in new capabilities and capacity for biologics, cell and gene therapies and drug product development and commercialization. For example, to support demand for gene therapies, Thermo Fisher will be doubling its viral vector manufacturing capacity with a new manufacturing site in Plainville, Mass. Construction of the 290,000-square-foot facility will be complete in 2022 and complements the company's recent expansions in Lexington and Cambridge, Mass., and Alachua, Fla. This week, STAT News will feature, "The STAT Guide to viral vectors, the linchpin of gene therapy," which covers the issues and considerations in engineering and manufacturing viral vectors.

Spotlight

Cultivation of cell aggregates

For many applications like disease modeling, drug toxicity assessment, and manufacture of stem cell-based products, three-dimensional (3D) cell aggregates are of great interest.  Researchers at the Instituto de Biologia Experimental e Tecnológica (iBET) in Portugal have tested the suitability of the Eppendorf DASbox® Mini Bioreactor System for the cultivation of the human tumor cell line H157 as 3D cell aggregates.

More featured news

Spotlight

Cultivation of cell aggregates

For many applications like disease modeling, drug toxicity assessment, and manufacture of stem cell-based products, three-dimensional (3D) cell aggregates are of great interest.  Researchers at the Instituto de Biologia Experimental e Tecnológica (iBET) in Portugal have tested the suitability of the Eppendorf DASbox® Mini Bioreactor System for the cultivation of the human tumor cell line H157 as 3D cell aggregates.

Related News

MEDICAL

GT Molecular, Rapidly Expanding Molecular Diagnostics Biotech, Launches Two Highly Sensitive Tests for the Dangerous UK Variant of SARS-CoV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes networks with a quick, exceptionally savvy technique to comprehend the measure of viral transmission inside a local area. Everybody inside a local area gives an example as a flush to the wastewater treatment office and a solitary wastewater test can cover a large number of individuals for a simple portion of what a clinical test for an individual expenses. Moreover, the presence of the infection in wastewater can go before nearby flare-ups locally by as long as seven days, giving wellbeing authorities time to prepare and increase testing. By applying this technique for local area wastewater checking to the recently coursing UK variation, GT Molecular is the first to go above and beyond and really "genotype the sewer".

Read More

RESEARCH

Chemistry42, an AI System from Insilico, has been Incorporated into UCB's Drug Discovery Programmes

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and expenses commonly connected with the plan, testing and commercialization of new drugs. Chemistry42™ v1.0 will be modified and conveyed on UCB's cloud-based supercomputing infrastructure. Chemistry42™ is an adaptable, easy to understand programming platform that incorporates man-made brainpower (AI) strategies with the fields of therapeutic and computational science for the plan of novel little atoms with client characterized druglike physicochemical properties. The platform is an adaptable conveyed web application equipped for running various assignments in equal very quickly. Container coordination and work process the executives consider unsurprising equipment freethinker asset distribution and the execution on one or the other cloud or neighborhood HPC infrastructures. "UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine. "Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide." About Insilico Medicine Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. About UCB UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Read More

RESEARCH

PharmAbcine to Present Updated Interim Data from the Ongoing Phase Ib Trial of Olinvacimab and Pembrolizumab Combination Therapy

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020. Positive data from the progressing security and tolerability study will feature wellbeing and certain viability information including ORR (Overall Response Rate) and DCR (Disease Control Rate) from 11 patients diagnosed with mTNBC. "We are excited to present highly encouraging data from our ongoing trial in the biggest breast cancer symposium. These data offer important insights into future development of the combo therapy," said Dr. Jin-San Yoo, CEO of PharmAbcine.

Read More

MEDICAL

GT Molecular, Rapidly Expanding Molecular Diagnostics Biotech, Launches Two Highly Sensitive Tests for the Dangerous UK Variant of SARS-CoV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes networks with a quick, exceptionally savvy technique to comprehend the measure of viral transmission inside a local area. Everybody inside a local area gives an example as a flush to the wastewater treatment office and a solitary wastewater test can cover a large number of individuals for a simple portion of what a clinical test for an individual expenses. Moreover, the presence of the infection in wastewater can go before nearby flare-ups locally by as long as seven days, giving wellbeing authorities time to prepare and increase testing. By applying this technique for local area wastewater checking to the recently coursing UK variation, GT Molecular is the first to go above and beyond and really "genotype the sewer".

Read More

RESEARCH

Chemistry42, an AI System from Insilico, has been Incorporated into UCB's Drug Discovery Programmes

Insilico Medicine | March 15, 2021

Insilico Medicine, an AI drug discovery company, reported that UCB will incorporate Insilico's Chemistry42™ into UCB's inward drug discovery pipeline. UCB's initial appropriation of Insilico Medicine's restrictive innovation will give UCB's researchers the capacity to plan novel hit compounds that fulfill various predefined boundaries quickly and smooth out lead enhancement. With the Chemistry42™ platform, UCB researchers will likewise lessen the endeavors and expenses commonly connected with the plan, testing and commercialization of new drugs. Chemistry42™ v1.0 will be modified and conveyed on UCB's cloud-based supercomputing infrastructure. Chemistry42™ is an adaptable, easy to understand programming platform that incorporates man-made brainpower (AI) strategies with the fields of therapeutic and computational science for the plan of novel little atoms with client characterized druglike physicochemical properties. The platform is an adaptable conveyed web application equipped for running various assignments in equal very quickly. Container coordination and work process the executives consider unsurprising equipment freethinker asset distribution and the execution on one or the other cloud or neighborhood HPC infrastructures. "UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine. "Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide." About Insilico Medicine Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. About UCB UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Read More

RESEARCH

PharmAbcine to Present Updated Interim Data from the Ongoing Phase Ib Trial of Olinvacimab and Pembrolizumab Combination Therapy

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020. Positive data from the progressing security and tolerability study will feature wellbeing and certain viability information including ORR (Overall Response Rate) and DCR (Disease Control Rate) from 11 patients diagnosed with mTNBC. "We are excited to present highly encouraging data from our ongoing trial in the biggest breast cancer symposium. These data offer important insights into future development of the combo therapy," said Dr. Jin-San Yoo, CEO of PharmAbcine.

Read More

More featured news